[go: up one dir, main page]

CO2018013298A2 - Anticuerpos anti-gitr y sus usos. - Google Patents

Anticuerpos anti-gitr y sus usos.

Info

Publication number
CO2018013298A2
CO2018013298A2 CONC2018/0013298A CO2018013298A CO2018013298A2 CO 2018013298 A2 CO2018013298 A2 CO 2018013298A2 CO 2018013298 A CO2018013298 A CO 2018013298A CO 2018013298 A2 CO2018013298 A2 CO 2018013298A2
Authority
CO
Colombia
Prior art keywords
gitr antibodies
gitr
antibodies
methods
glucocorticoid
Prior art date
Application number
CONC2018/0013298A
Other languages
English (en)
Inventor
Frank Delfino
Dimitris Skokos
Bei Wang
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of CO2018013298A2 publication Critical patent/CO2018013298A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

En el presente documento se proporcionan anticuerpos y fragmentos de unión a antígeno de los mismos que se unen específicamente al receptor del factor de necrosis tumoral inducido por glucocorticoides (GITR) y métodos para usarlos, incluidos, por ejemplo, métodos de tratamiento que los usan.
CONC2018/0013298A 2016-06-10 2018-12-07 Anticuerpos anti-gitr y sus usos. CO2018013298A2 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662348353P 2016-06-10 2016-06-10
US201662432023P 2016-12-09 2016-12-09
US201762500312P 2017-05-02 2017-05-02
PCT/US2017/036818 WO2017214548A1 (en) 2016-06-10 2017-06-09 Anti-gitr antibodies and uses thereof

Publications (1)

Publication Number Publication Date
CO2018013298A2 true CO2018013298A2 (es) 2019-02-19

Family

ID=59078260

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0013298A CO2018013298A2 (es) 2016-06-10 2018-12-07 Anticuerpos anti-gitr y sus usos.

Country Status (19)

Country Link
US (3) US10738126B2 (es)
EP (2) EP4344748A3 (es)
JP (2) JP7162535B2 (es)
KR (1) KR102495601B1 (es)
CN (1) CN109563170B (es)
AU (1) AU2017278193B9 (es)
BR (1) BR112018075434A2 (es)
CA (1) CA3027121A1 (es)
CL (1) CL2018003515A1 (es)
CO (1) CO2018013298A2 (es)
IL (1) IL263273B2 (es)
MA (1) MA45233A (es)
MX (2) MX2018015350A (es)
MY (1) MY200162A (es)
PH (1) PH12018502502A1 (es)
SG (1) SG11201810525XA (es)
UA (1) UA128687C2 (es)
WO (1) WO2017214548A1 (es)
ZA (1) ZA201807920B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR097306A1 (es) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
KR102495601B1 (ko) 2016-06-10 2023-02-06 리제너론 파마슈티칼스 인코포레이티드 항-gitr 항체 및 그것의 사용
CA3037380A1 (en) 2016-10-11 2018-04-19 Agenus Inc. Anti-lag-3 antibodies and methods of use thereof
CN110168105B (zh) 2016-12-09 2024-05-24 瑞泽恩制药公司 用于对t细胞受体进行测序的系统和方法及其用途
AU2019233581B2 (en) * 2018-03-13 2025-08-28 Cancer Research Technology Limited Anti-CD25 for tumour specific cell depletion
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CA3127696A1 (en) 2019-02-12 2020-08-20 Regeneron Pharmaceuticals, Inc. Compositions and methods for using bispecific antibodies to bind complement and a target antigen
RU2734432C1 (ru) 2019-04-23 2020-10-16 Закрытое Акционерное Общество "Биокад" Моноклональное антитело, которое специфически связывается с GITR
US20230064703A1 (en) * 2020-01-02 2023-03-02 Nanjing GenScript Biotech Co., Ltd. Anti-gitr antibodies and uses thereof
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
WO2021178814A1 (en) * 2020-03-06 2021-09-10 Regeneron Pharmaceuticals, Inc. Anti-gitr antibodies and uses thereof
CN116761622A (zh) * 2021-01-08 2023-09-15 苏州丁孚靶点生物技术有限公司 药物产品及其用途
TW202237642A (zh) * 2021-01-08 2022-10-01 美商１０Ｘ基因組學有限公司 對冠狀病毒具有特異性的抗原結合多肽及其用途
KR102475255B1 (ko) * 2021-05-10 2022-12-09 메디맵바이오 주식회사 항-gitr 항체 및 이의 용도
CN118946582A (zh) 2022-03-15 2024-11-12 耶达研究及发展有限公司 抗糖皮质激素诱导的tnfr相关（gitr）蛋白抗体及其用途

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
WO1998006842A1 (en) 1996-08-16 1998-02-19 Schering Corporation Mammalian cell surface antigens; related reagents
US6111090A (en) 1996-08-16 2000-08-29 Schering Corporation Mammalian cell surface antigens; related reagents
US6689607B2 (en) 1997-10-21 2004-02-10 Human Genome Sciences, Inc. Human tumor, necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
US6503184B1 (en) 1997-10-21 2003-01-07 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
CA2308365A1 (en) 1997-11-18 1999-05-27 Genentech, Inc. Dna19355 polypeptide, a tumor necrosis factor homolog
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
EP1462114A1 (en) 2003-03-28 2004-09-29 Universiteit Utrecht Holding B.V. Methods and means to suppress symptons of an allergic disease by inhibiting the glucocorticoid-induced tumor necrosis factor receptor (GRIT or TNFRSF18)
NZ543654A (en) 2003-05-23 2009-05-31 Wyeth Corp GITR ligand and GITR ligand-related molecules and antibodies and uses thereof
US20060099171A1 (en) 2004-11-05 2006-05-11 Masahide Tone Mouse glucocorticoid-induced TNF receptor ligand is costimulatory for T cells
ES2657443T3 (es) 2005-03-25 2018-03-05 Gitr, Inc. Anticuerpos anti-GITR y usos de los mismos
US20110212086A1 (en) 2006-01-19 2011-09-01 Genzyme Corporation GITR Antibodies For The Treatment of Cancer
WO2007084775A2 (en) 2006-01-20 2007-07-26 The Trustees Of The University Of Pennsylvania Compositions and methods for modulation of suppressor t cell activation
CA2652976C (en) 2006-06-02 2015-08-11 Regeneron Pharmaceuticals, Inc. High affinity antibodies to human il-6 receptor
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
US8591886B2 (en) 2007-07-12 2013-11-26 Gitr, Inc. Combination therapies employing GITR binding molecules
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
CA2772613C (en) 2009-09-03 2020-03-10 Schering Corporation Anti-gitr antibodies
WO2013039954A1 (en) 2011-09-14 2013-03-21 Sanofi Anti-gitr antibodies
EP2765193B1 (en) 2011-10-07 2017-08-09 Mie University Chimeric antigen receptor
KR101566538B1 (ko) 2012-06-08 2015-11-05 국립암센터 신규한 Ｔｈ17 세포 전환용 에피토프 및 이의 용도
AR097306A1 (es) * 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
SMT202100116T1 (it) 2014-05-28 2021-05-07 Agenus Inc Anticorpi anti-gitr e metodi di utilizzo degli stessi
DK3151921T3 (da) * 2014-06-06 2019-12-02 Bristol Myers Squibb Co Antistoffer mod glucocorticoid-induceret tumornekrosefaktor- receptorer (gitr) og anvendelser deraf
JP2017531427A (ja) 2014-10-03 2017-10-26 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド グルココルチコイド誘導腫瘍壊死因子受容体（ｇｉｔｒ）抗体およびその使用法
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
MX382902B (es) * 2014-10-31 2025-03-13 Oncomed Pharm Inc Inhibidor de la vía noth en combinación con un agente inmunoterapéutico para usarse en el tratamiento de cáncer.
KR102495601B1 (ko) 2016-06-10 2023-02-06 리제너론 파마슈티칼스 인코포레이티드 항-gitr 항체 및 그것의 사용

Also Published As

Publication number Publication date
CL2018003515A1 (es) 2019-03-08
AU2017278193A1 (en) 2018-12-13
IL263273A (en) 2018-12-31
EP4344748A2 (en) 2024-04-03
EP4344748A3 (en) 2024-06-12
ZA201807920B (en) 2024-01-31
IL263273B1 (en) 2025-06-01
US11414494B2 (en) 2022-08-16
PH12018502502A1 (en) 2019-04-08
US20210147565A1 (en) 2021-05-20
NZ748619A (en) 2024-05-31
MA45233A (fr) 2019-04-17
KR102495601B1 (ko) 2023-02-06
UA128687C2 (uk) 2024-10-02
US20170355774A1 (en) 2017-12-14
EP3468999B1 (en) 2024-01-10
CA3027121A1 (en) 2017-12-14
AU2017278193B9 (en) 2024-02-01
JP2019521098A (ja) 2019-07-25
WO2017214548A1 (en) 2017-12-14
MY200162A (en) 2023-12-09
JP2022159476A (ja) 2022-10-17
IL263273B2 (en) 2025-10-01
JP7162535B2 (ja) 2022-10-28
EP3468999A1 (en) 2019-04-17
US10738126B2 (en) 2020-08-11
AU2017278193B2 (en) 2024-01-18
CN109563170B (zh) 2023-10-13
MX2018015350A (es) 2019-08-26
KR20190020297A (ko) 2019-02-28
MX2022014695A (es) 2022-12-16
BR112018075434A2 (pt) 2019-03-19
SG11201810525XA (en) 2018-12-28
CN109563170A (zh) 2019-04-02
US20230042324A1 (en) 2023-02-09

Similar Documents

Publication Publication Date Title
CO2018013298A2 (es) Anticuerpos anti-gitr y sus usos.
MX381046B (es) Anticuerpos anti-csf1r e inhibidores de pd-1/pd-l1, y usos de los mismos para el tratamiento de cáncer remisión a las solicitudes relacionadas.
ECSP17011657A (es) Conjugados de fármacos con anticuerpos anti-cdh6
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
MX2022014867A (es) Anticuerpos especificos del receptor de poliovirus humano (rvp).
CL2016003136A1 (es) Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (gitr) y sus usos
MX2019006954A (es) Terapia de combinacion de anticuerpos biespecificos anti-cd20/anti-cd3 y agonistas de 4-1bb (cd137).
CO2017004516A2 (es) Anticuerpos anti-ox40 humanizados
HUE061874T2 (hu) Anti-PD-1 antitestek és besugárzás kombinált alkalmazása a rák kezelésére
CO2018005433A2 (es) Conjugados de fármaco de anticuerpo her2 específicos de sitio
CL2018003366A1 (es) Anticuerpos anti -cd40 y sus usos
MX2016012880A (es) Cadena j modificada.
MX2016015614A (es) Anticuerpos anti proteína relacionada con el receptor del factor de necrosis tumoral inducida por glucocorticóides (gitr) y sus métodos de uso.
CL2016001871A1 (es) Anticuerpos humanos para pd-1
MX2018003629A (es) Anticuerpos anti-pd1 y metodos de uso.
MX2018005551A (es) Anticuerpos que se unen especificamente a pd-1, y sus usos.
CR20170131A (es) Anticuerpos anti-her2 e inmunoconjugados
CL2018001722A1 (es) Nuevos anticuerpos anti-mfi2 y métodos de uso (divisional solicitud 201700506)
UY35399A (es) Conjugados de fármacos con anticuerpos
CO2018005752A2 (es) Nuevos anticuerpos anti-claudina y sus métodos de uso
DOP2016000283A (es) Anticuerpos anti-rnf43 novedosos y métodos para su uso
MX2016010433A (es) Anticuerpos anti-jagged1 y metodos de uso.
MX2016016301A (es) Procesos de siembra en serie y usos de los mismos.
CL2016001753A1 (es) Anticuerpo monoclonal humanizado que se une específicamente a netrina-1, composiciones farmacéuticas y usos del anticuerpo para el tratamiento del cáncer
MX2017001686A (es) Anticuerpos anti-ceramida.